AAAAAA

   
Results: 1-25 | 26-50 | 51-59
Results: 1-25/59
Production and resource use efficiencies in N- and P-limited tropical forests: A comparison of responses to long-term fertilization
Authors: Harrington, RA Fownes, JH Vitousek, PM
Citation: Ra. Harrington et al., Production and resource use efficiencies in N- and P-limited tropical forests: A comparison of responses to long-term fertilization, ECOSYSTEMS, 4(7), 2001, pp. 646-657
American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes - A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee)
Authors: Cannon, CP Battler, A Brindis, RG Cox, JL Ellis, SG Every, NR Flaherty, JT Harrington, RA Krumholz, HM Simoons, ML Van de Werf, FJJ Weintraub, WS Mitchell, KR Morrisson, SL Brandis, RG Anderson, HV Cannom, DS Chitwood, WR Cigarroa, JE Collins-Nakai, RL Ellis, SG Gibbons, RJ Grover, FL Heidenreich, PA Khandheria, BK Knoebel, SB Krumholz, HL Malenka, DJ Mark, DB McKay, CR Passamani, ER Radford, MJ Riner, RN Schwartz, JB Shaw, RE Shemin, RJ Van Fossen, DB Verrier, ED Watkins, MW Phoubandith, DR Furnelli, T
Citation: Cp. Cannon et al., American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes - A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee), J AM COL C, 38(7), 2001, pp. 2114-2130
Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up
Authors: Alexander, KP Newby, LK Hellkamp, AS Harrington, RA Peterson, ED Kopecky, S Langer, A O'Gara, P O'Connor, CM Daly, RN Califf, RM Khan, S Fuster, V
Citation: Kp. Alexander et al., Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up, J AM COL C, 38(1), 2001, pp. 1-7
Prognostic value of ST segment depression in acute coronary syndromes: Insights from PARAGON-A applied to GUSTO-IIb
Authors: Kaul, P Fu, YL Chang, WC Harrington, RA Wagner, GS Goodman, SG Granger, CB Moliterno, DJ Van de Werf, F Califf, RN Topol, EJ Armstrong, PW
Citation: P. Kaul et al., Prognostic value of ST segment depression in acute coronary syndromes: Insights from PARAGON-A applied to GUSTO-IIb, J AM COL C, 38(1), 2001, pp. 64-71
Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes
Authors: Greenbaum, AB Harrington, RA Hudson, MP MacAulay, CM Wilcox, RG Simoons, ML Berdan, LG Guerci, A Cokkinos, DV Kitt, MM Lincoff, AM Topol, EJ Califf, RM Ohman, EM
Citation: Ab. Greenbaum et al., Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes, J AM COL C, 37(2), 2001, pp. 492-498
Shifting the open-artery hypothesis downstream: The quest for optimal reperfusion
Authors: Roe, MT Ohman, EM Maas, ACP Christenson, RH Mahaffey, KW Granger, CB Harrington, RA Califf, RM Krucoff, MW
Citation: Mt. Roe et al., Shifting the open-artery hypothesis downstream: The quest for optimal reperfusion, J AM COL C, 37(1), 2001, pp. 9-18
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study
Authors: Aronow, HD Topol, EJ Roe, MT Houghtaling, PL Wolski, KE Lincoff, AM Harrington, RA Califf, RM Ohman, EM Kleiman, NS Keltai, M Wilcox, RG Vahanian, A Armstrong, PW Lauer, MS
Citation: Hd. Aronow et al., Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study, LANCET, 357(9262), 2001, pp. 1063-1068
Intravenous thrombolysis in acute myocardial infarction
Authors: Ohman, EM Harrington, RA Cannon, CP Agnelli, G Cairns, JA Kennedy, JW
Citation: Em. Ohman et al., Intravenous thrombolysis in acute myocardial infarction, CHEST, 119(1), 2001, pp. 253S-277S
Antithrombotic therapy in patients undergoing percutaneous coronary intervention
Authors: Popma, JJ Ohman, EM Weitz, J Lincoff, M Harrington, RA Berger, P
Citation: Jj. Popma et al., Antithrombotic therapy in patients undergoing percutaneous coronary intervention, CHEST, 119(1), 2001, pp. 321S-336S
Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes - Prospective analysis from PURSUIT
Authors: Tardiff, BE Jennings, LK Harrington, RA Gretler, D Potthoff, RF Vorchheimer, DA Eisenberg, PR Lincoff, AM Labinaz, M Joseph, DM McDougal, MF Kleiman, NS
Citation: Be. Tardiff et al., Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes - Prospective analysis from PURSUIT, CIRCULATION, 104(4), 2001, pp. 399-405
Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acutecoronary syndromes - Observations from the platelet IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial
Authors: Lauer, MA Houghtaling, PL Peterson, JG Granger, CB Bhatt, DL Sapp, SK Simoons, ML Harrington, RA Topol, EJ Lincoff, AM
Citation: Ma. Lauer et al., Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acutecoronary syndromes - Observations from the platelet IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial, CIRCULATION, 104(23), 2001, pp. 2772-2777
Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status - The PARAGON-B troponin T substudy
Authors: Newby, LK Ohman, EM Christenson, RH Moliterno, DJ Harrington, RA White, HD Armstrong, PW Van de Werf, F Pfisterer, M Hasselblad, V Califf, RM Topol, EJ
Citation: Lk. Newby et al., Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status - The PARAGON-B troponin T substudy, CIRCULATION, 103(24), 2001, pp. 2891-2896
Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS)
Authors: O'Connor, CM Gattis, WA Hellkamp, AS Langer, A Larsen, RL Harrington, RA Berkowitz, SD O'Gara, PT Kopecky, SL Gheorghiade, M Daly, R Califf, RM Fuster, V
Citation: Cm. O'Connor et al., Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS), AM J CARD, 88(5), 2001, pp. 541-546
Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: Results from the PURSUIT trial
Authors: Al-Khatib, SM Pieper, KS Lee, KL Mahaffey, KW Hochman, JS Pepine, CJ Kopecky, SL Akkerhuis, M Stepinska, J Simoons, ML Topol, EJ Califf, RM Harrington, RA
Citation: Sm. Al-khatib et al., Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: Results from the PURSUIT trial, AM J CARD, 88(1), 2001, pp. 76-79
Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes
Authors: Peterson, JG Topol, EJ Roe, MT Sapp, SK Lincoff, AM Deckers, JW Blackstone, EH Harrington, RA Califf, RM Lauer, MS
Citation: Jg. Peterson et al., Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes, AM J CARD, 87(5), 2001, pp. 532-536
Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial
Authors: Cohen, MG Pacchiana, CM Corbalan, R Perez, JEI Ponte, CI Oropeza, ES Diaz, R Paolasso, E Izasa, D Rodas, MA Urrutia, CE Harrington, RA Topol, EJ Califf, RM
Citation: Mg. Cohen et al., Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, AM HEART J, 141(3), 2001, pp. 391-401
Optimizing treatment of acute coronary syndromes with GP IIb/IIIa inhibitors - Proceedings of the satellite symposium to the XXIst Congress of the European Society of Cardiology, Barcelona, Spain, August 1999 - Foreword
Authors: Simoons, ML Harrington, RA
Citation: Ml. Simoons et Ra. Harrington, Optimizing treatment of acute coronary syndromes with GP IIb/IIIa inhibitors - Proceedings of the satellite symposium to the XXIst Congress of the European Society of Cardiology, Barcelona, Spain, August 1999 - Foreword, EUR H J SUP, 2(C), 2000, pp. C1-C1
New findings with eptifibatide
Authors: Harrington, RA Vahanian, A
Citation: Ra. Harrington et A. Vahanian, New findings with eptifibatide, EUR H J SUP, 2(C), 2000, pp. C10-C14
"Rescue"' platelet GP IIb/IIIa inhibitor therapy in percutaneous coronary intervention: Bailing out of a sunken ship
Authors: Kandzari, DE Tcheng, JE Harrington, RA Sketch, MH
Citation: De. Kandzari et al., "Rescue"' platelet GP IIb/IIIa inhibitor therapy in percutaneous coronary intervention: Bailing out of a sunken ship, J INVAS CAR, 12(10), 2000, pp. 502-504
Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation
Authors: Hasdai, D Harrington, RA Hochman, JS Califf, RM Battler, A Box, JW Simoons, ML Deckers, J Topol, EJ Holmes, DR
Citation: D. Hasdai et al., Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation, J AM COL C, 36(3), 2000, pp. 685-692
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy
Authors: Sane, DC Damaraju, LV Topol, EJ Cabot, CF Mascelli, MA Harrington, RA Simoons, ML Califf, RM
Citation: Dc. Sane et al., Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy, J AM COL C, 36(1), 2000, pp. 75-83
Optimal dosing of a platelet glycoprotein (GP) IIb/IIIa antagonist, lamifiban, using renal-based algorithms, in patients with acute coronary syndromes (ACS): Results from the PARAGON B study
Authors: Harrington, RA
Citation: Ra. Harrington, Optimal dosing of a platelet glycoprotein (GP) IIb/IIIa antagonist, lamifiban, using renal-based algorithms, in patients with acute coronary syndromes (ACS): Results from the PARAGON B study, J AM COL C, 36(1), 2000, pp. 319-319
Cardiac enzyme elevations after percutaneous coronary intervention: Myonecrosis, the coronary microcirculation and mortality
Authors: Harrington, RA
Citation: Ra. Harrington, Cardiac enzyme elevations after percutaneous coronary intervention: Myonecrosis, the coronary microcirculation and mortality, J AM COL C, 35(5), 2000, pp. 1142-1144
What have we learned from the recent large trials in acute coronary syndromes without ST-segment elevation?
Authors: Harrington, RA Simoons, ML
Citation: Ra. Harrington et Ml. Simoons, What have we learned from the recent large trials in acute coronary syndromes without ST-segment elevation?, EUR HEART J, 21(9), 2000, pp. 702-704
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes - Results from PURSUIT
Authors: Akkerhuis, KM Deckers, JW Boersma, E Harrington, RA Stepinska, J Mahaffey, KW Wilcox, RG Lincoff, AM Keltai, M Topol, EJ Califf, RM Simoons, ML
Citation: Km. Akkerhuis et al., Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes - Results from PURSUIT, EUR HEART J, 21(5), 2000, pp. 371-381
Risultati: 1-25 | 26-50 | 51-59